Klacid Hp Drug Interactions

Klacid: Clarithromycin has been shown not to interact with oral contraceptives. As with other macrolide antibiotics, the use of clarithromycin in patients concurrently taking drugs metabolised by the cytochrome P-450 system (eg, warfarin, ergot alkaloids, triazolam, midazolam, disopyramide, lovastatin, phenytoin and cyclosporin) may be associated with elevations in serum levels of these other drugs. The administration of clarithromycin to patients who are receiving theophylline has been associated with an increase in serum theophylline levels and potential theophylline toxicity.
The use of clarithromycin in patients receiving warfarin may result in potentiation of the effects of warfarin. Prothrombin time should be frequently monitored in these patients. The effects of digoxin may be potentiated with concomitant administration of Klacid. Monitoring of serum digoxin levels should be considered. Clarithromycin may potentiate the effects of carbamazepine due to a reduction in the rate of excretion. Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady state of zidovudine by 1-2 hrs. No such reaction has been reported in children.
Controloc: Controloc may reduce the absorption of drugs whose bioavailability is pH-dependent (eg, ketoconazole). Pantoprazole is metabolized in the liver via the cytochrome P-450 enzyme system. An interaction of pantoprazole with other drugs or compounds which are metabolized using the same enzyme system cannot be excluded. No clinically significant interactions were, however, observed in specific tests with a number of such drugs or compounds eg, carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, nifedipine, phenprocoumon, phenytoin, theophylline, warfarin and an oral contraceptive. There were also no interactions with concomitantly administered antacids. Human kinetic interaction studies have been performed administering pantoprazole concomitantly with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.
Ospamox: Concomitant ingestion of allopurinol may promote the occurrence of skin rashes. The underlying mechanism is still poorly understood. As penicillins like amoxicillin only act on proliferating microorganisms, they should not be combined with bacteriostatic antibiotics eg, tetracyclines and chloramphenicol. If suggested by the outcome of susceptibility tests, combinations with other bactericidal antibiotics (cephalosporins, aminoglycoside) may be used. The concomitant administration of probenecid (eg, 0.5 g 4 times a day orally); contraindicated in children <2 years produces sustained and higher plasma level by suppressing renal elimination. Conversely, tissue distribution and diffusion of Ospamox may be reduced by probenecid. Like other antibiotics, aminopenicillin may rarely reduce the efficacy of oral contraceptives. Concomitant antacid intake reduces amoxicillin absorption. Non-enzymatic urinary glucose tests may be false positive. Urobilinogen tests may also be impaired.